The MONALEESA-2 trial [106] evaluated ribociclib as a first-line treatment for advanced HR+/HER2- breast cancer in postmenopausal women, showing a significant improvement in progression-free survival and overall survival. Here, ERBB2 is linked to breast carcinoma.